Clinical Supervision for Mental Health Nurses in NI (PDF 135 KB)

Best Practice Guidelines

Draft Protection of Children and Vulnerable Adults (NI) Order (PDF 30 KB)

Explanatory Memorandum

Key Indicators of PSS for NI (2002)

Key Indicators of PSS for NI (2002)

The Health and Personal Social Services (Quality, Improvement and Regulation) NI Order 2003 (PDF 178 KB)

Draft Statutory Instruments

Drug and Alcohol Use Among Young People in NI (PDF 424 KB)

A Secondary Analysis of Drug and Alcohol Use Surveys - Final Report

Prevalence of Problem Heroin Use in NI (PDF 227 KB)

Mar-02

A Strategy for Nursing Midwifery and Health Visiting in NI (PDF 180KB)

This study was designed to examine critically the impact of a government-led policy document upon community nursing, midwifery and health visiting practice in Northern Ireland (Strategy for Nursing, Midwifery and Health Visiting in Northern Ireland. Action Plan for Community Nurses, Midwives and Health Visitors, Working Together: A Focus on Health and Social Well-being, DHSS, 1996). The total number of participants was (n=409) and the eleven Health and Personal Social Services Trusts in NI were represented in the sample group which consisted of 93% females and 7% males. A questionnaire containing twenty items was designed and a pilot study was carried out with twenty-five community practitioners. Following the pilot study appropriate modifications were made to the questionnaire. åÊ

Nursing Services for the Acutely Ill Child in NI (PDF 216 KB)

Report of a Working Group

Tractament amb EPOCH a dosi ajustada i Rituximab en pacients no tractats amb LNH-B de cèl.lula gran de mal pronòstic

Aquest estudi multicèntric, fase IV analitza l’eficàcia i la seguretat del tractament amb dosi ajustada d’EPOCH amb Rituximab en infusió continua, en pacients no tractats prèviament amb mal pronòstic diagnosticats de limfomes B de cèl.lula gran. Material i mètodes. S’inclogueren 81 pacients, 68 d’aquests diagnosticats de Limfoma B difús de cèl.lula gran, 7 de Limfoma fol.licular grau III i 6 de Limfoma B primari de mediastí. Eren pacients de mal pronòstic segons IPI≥2 o IPIae≥1, ECOG/PS 0-4, estadi II-IV (estadi I si malaltia voluminosa al diagnòstic). Resultats. La edat mitjana era de 52 anys (rang, 21-77 anys), 92,5% d’alt risc segons l’IPIae. Es va obtenir resposta completa (RC i RCi) en el 79% dels pacients, la supervivència global i la supervivència lliure d’esdeveniment, a la mediana del temps de seguiment (34,3 mesos) va ser de 68% i 63,2%, respectivament. La supervivència lliure de malaltia als 5 anys va ser de 72,2% pels pacients que van assolir RC/RCi. Cap dels factors de risc de l’IPI o IPIae, ni els índexs per ells mateixos van resultar amb associació estadísticament significativa a la OS o PFS. Només es va obtenir associació entre els nivells de ß2 microglobulina (&3,5mg/l) i la PFS i OS (p=0,075 i p=0,015, respectivament). Es van reportar 54 episodis de neutropènia febril (11,5% dels cicles); i es van morir 27 pacients, 15 (55,5%) degut a progressió de la malaltia i 9 (33,3%) degut a sepsi o infecció grau 4. Conclusions. Els resultats aconseguits amb la combinació de Rituximab i DA-EPOCH mostren uns resultats prometedors i amb nivells de toxicitat molt acceptables en els pacients d’alt risc diagnosticats de Limfomes B de cèl.lula gran no tractats prèviament.

Health Inequalities: NI Health % Social Care Inequalities Monitoring System - Regional 2014

Key Points: Health outcomes are generally worse in the most deprived areas in Northern Ireland when compared both with those witnessed in the region generally and in the least deprived areas. Large differences (health inequality gaps) continue to exist for a number of different health measures. åá Males in the 20% most deprived areas could expect, on average, to live 4.3 fewer years than the NI average and 7.3 fewer years than those in the 20% least deprived areas.åá Female life expectancy in the most deprived areas was 2.6 years less than the regional average and 4.3 years less than that in the least deprived areas.åá The overall death rate for males as measured by the All Age All Cause Mortality (AAACM) rate was a fifth higher in the most deprived areas (1,567 deaths per 100,000 population) than the NI average (1,304 deaths per 100,000 population), and 44% higher than in the least deprived areas (1,090 deaths per 100,000 population).åá The overall death rate for females (AAACM) in the most deprived areas (1,093 deaths per 100,000 population) was 17% higher than regionally (935 deaths per 100,000 population), and a third higher than in the least deprived areas (829 deaths per 100,000 population).åá The suicide rate in the most deprived areas (30.7 deaths per 100,000 population) was three times that in the least deprived areas (10.1 deaths per 100,000 population). All HSCIMS reports are published on the Departmental website at: http://www.dhsspsni.gov.uk/index/statistics/health-inequalities.htm

Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).

Purpose: To compare the long-term outcome of treatment with concomitant cisplatin and hyperfractionated radiotherapy versus treatment with hyperfractionated radiotherapy alone in patients with locally advanced head and neck cancer.Methods and Materials: From July 1994 to July 2000, a total of 224 patients with squamous cell carcinoma of the head and neck were randomized to receive either hyperfractionated radiotherapy alone (median total dose, 74.4 Gy; 1.2 Gy twice daily; 5 days per week) or the same radiotherapy combined with two cycles of cisplatin (20 mg/m(2) for 5 consecutive days during weeks 1 and 5). The primary endpoint was the time to any treatment failure; secondary endpoints were locoregional failure, metastatic failure, overall survival, and late toxicity assessed according to Radiation Therapy Oncology Group criteria.Results: Median follow-up was 9.5 years (range, 0.1-15.4 years). Median time to any treatment failure was not significantly different between treatment arms (hazard ratio [HR], 1.2 [95% confidence interval [CM 0.9-1.7; p = 0.17]). Rates of locoregional failure-free survival (HR, 1.5 [95% CI, 1.1-2.1;p = 0.021), distant metastasis-free survival (HR, 1.6 [95% CI, 1.1-2.5; p = 0.021), and cancer-specific survival (HR, 1.6 [95% CI, 1.0-2.5;p = 0.03]) were significantly improved in the combined-treatment arm, with no difference in major late toxicity between treatment arms. However, overall survival was not significantly different (HR, 1.3 [95% CI, 0.9-1.8; p = 0.11]).Conclusions: After long-term follow-up, combined-treatment with cisplatin and hyperfractionated radiotherapy maintained improved rates of locoregional control, distant metastasis-free survival, and cancer-specific survival compared to that of hyperfractionated radiotherapy alone, with no difference in major late toxicity. (C) 2012 Elsevier Inc.